BRCA2 germline pathogenic in HER2-negative metastatic breast: olaparib (OlympiAD) and tal...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRCA2-GERMLINE-BREAST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-BREAST |
| Sources | SRC-CIVIC SRC-ESMO-BREAST-EARLY-2024 SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Actionability Facts
| Biomarker | BIO-BRCA1-BRCA2-GERMLINE |
|---|---|
| Variant | BRCA2 germline pathogenic |
| Disease | DIS-BREAST |
| ESCAT tier | IA |
| Recommended combinations | olaparib monotherapy, talazoparib monotherapy, olaparib adjuvant 1y, platinum-based chemo (TNBC) |
| Evidence summary | BRCA2 germline pathogenic in HER2-negative metastatic breast: olaparib (OlympiAD) and talazoparib (EMBRACA) improve PFS; in early-stage high-risk HER2-negative, 1y adjuvant olaparib improves iDFS and OS (OlympiA). ESCAT IA / OncoKB Level 1. |
Notes
Cascade testing mandatory. BRCA2 male carriers face elevated breast cancer (~7% lifetime) and prostate cancer risk.
Used By
No reverse references found in the YAML corpus.